title: A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
abstract: Effective treatment with factor IX (FIX) requires a thorough consideration of the properties of the concentrate to be used as replacement therapy, to date, the only available treatment for haemophilia B. The aim of the study was to determine the pharmacokinetics, clinical efficacy and safety in routine clinical use of AlphaNine(®) , a high-purity human FIX concentrate. This open, single-arm, multicentre, non-randomized trial included 25 subjects (age ≥ 12) with moderate/severe haemophilia B. Pharmacokinetics was assessed at baseline and after a 6-month follow-up. The degree of haemostasis control achieved was evaluated during a 12-month follow-up. Safety was evaluated in terms of tolerance, thrombogenicity, immunogenicity and viral safety. Mean recovery was 1.01 ± 0.19 IU dL(-1) per IU kg(-1) at baseline and 1.23 ± 0.34 IU dL(-1) per IU kg(-1) 6 months later. Terminal half-life was 34.5 ± 6.2 h and 33.7 ± 5.4 h, respectively. Ratios of each parameter between the two pharmacokinetic studies were all close to 1. A total of 1,576,890 IU AlphaNine(®) were administered in 889 infusions (mean dose per infusion: 1774 IU; 3.2 infusions per month per patient). The main reasons for infusion were mild/moderate bleeding (62.3%) and prophylaxis (20.5% continuous, 15.6% intermittent). Overall, 93.0% of the efficacy assessments were rated as excellent/good and 88.8% of bleedings resolved after the first infusion. Twenty-one adverse events were reported in eight patients, none of which was considered related to the study medication. AlphaNine(®) showed a pharmacokinetic profile in agreement with that of other plasma-derived FIX concentrates and provides safe and clinically effective substitution therapy for patients with haemophilia B.
authors.affiliation: National Center of Hematology, Sofia, Bulgaria. t.lissitchkov@yahoo.com
authors.forename: T
authors.initials: T
authors.lastname: Lissitchkov
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: K
authors.initials: K
authors.lastname: Zavilska
authors.forename: P
authors.initials: P
authors.lastname: Laguna
authors.forename: L
authors.initials: L
authors.lastname: Gercheva
authors.forename: A
authors.initials: A
authors.lastname: Antonov
authors.forename: N
authors.initials: N
authors.lastname: Cabrera
authors.forename: J A
authors.initials: JA
authors.lastname: Aznar
authors.forename: M K
authors.initials: MK
authors.lastname: Woodward
authors.forename: A
authors.initials: A
authors.lastname: Páez
mesh_terms: D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005164:Factor IX / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005500:Follow-Up Studies; D002836:Hemophilia B / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D055815:Young Adult
chemical_list: D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005164:Factor IX